Health Economics›Chronic myeloid leukemia›Chronic phase relapsed or refractory

Chronic phase relapsed or refractory

Chronic myeloid leukemia · 12 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Asciminib monotherapy Variant #01	—	R 199 106	28d	—	—	~2	~R 398 211 indirect	—
Nilotinib monotherapy Variant #01	—	R 28 002	28d	—	—	~66	~R 1 848 148 indirect	—
Dasatinib monotherapy Variant #01	—	R 12 899	28d	—	—	~2	~R 25 797 indirect	—
Busulfan monotherapy Variant #01	—	R 9 802	28d	—	—	~2	~R 19 604 indirect	—
BuCyTBI, then allo HSCT Variant #01 Partial	—	R 3 276	—	—	—	~1	~R 3 276 indirect	—
Imatinib monotherapy Variant #16	—	R 2 801	28d	~20.0 mo	~53.0 mo	~2	~R 5 603 PFS proxy · indirect	8
Cyclophosphamide and TBI, then allo HSCT Variant #01 Partial	—	R 1 176	—	—	—	~1	~R 1 176 indirect	—
Olverembatinib monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—
Omacetaxine monotherapy Variant #01 Partial	—	—	28d	—	—	~27	—	—
Bosutinib monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—
Interferon alfa-2b and DLI Variant #01 Partial	—	—	—	—	—	~1	—	—
Ponatinib monotherapy Variant #01 Partial	—	—	28d	—	—	~2	—	—

12 of 12 regimens shown